Обзоры (стр. 4 )

10.        Gross KL, David M, Neskey, Nitasha, Manchanda, Stanislawa Weremowicz, Michael S, Kleinman, Romana A. Nowak, Azra H. Ligon, Piere Rogalla, Klaus Drechsler, Jorn Bullerdiek, Cynthia C. Morton. HMGA2 expression in uterine leiomyomata and myometrium: quantitative analysis and tissue culture studies. Genes Chromosomes Cancer. 2003;38:1:68—79. https://doi. org/10.1002/gcc.10240

11.        Rogalla P, Drechsler K, Frey G, Hennig Y, Helmke B, Bonk U, Bullerdiek J. HMGI-C expression patterns in human tissues. Implications for the genesis of frequent mesenchymal tumors. Am J Pathol. 1996;149:3:775—779. ISSN: 0002-9440

12.        Cattaruzzi G, Sandro Altamura S, Michela A. Tessari, Rustighi A.,Giancotti V., Pucillo C., Guidalberto Manfioletti G. The second AT-hook of the architectural transcription factor HMGA2 is determinant for nuclear localization and function. Nucleic Acids Res. 2007;35:6:1751—1760. https://doi. org/10.1093/nar/gkl1106

13.        Li AYJ, Boo LM, Wang S-Y, Lin HH, Wang CCC, Yen Y, Chen BPC, Chen DJ, Ann ppression of nonhomologous end joining repair by overexpression of HMGA2. Cancer Res. 2009;69:14:5699—5706.  https://doi. org/10,1158/0008-5472.CAN-08-4833

14.        Bullerdiek J, Rommel ment re: HMGA2 is a negative regulator of DNAPK pathway. Cancer Res. 2010;70:1742. https://doi. org/10.1158/0008-5472.CAN-09-3081

15.        Schoenmakers, EFPM, Bunt J, Hermers, L, Schepens, M, Merkx G, Janssen B, Kersten M, Huys, E, Pauwels P, Debiec-Rychter M. and van Kessel AG. Identification of CUX1 as the recurrent chromosomal band 7q22 target gene in human uterine leiomyoma. Genes Chromosom. Cancer. 2013;52:1:11—23.  https://doi. org/10.1002/gcc.22001

16.        Rein MS, Powell WL, Walters FC, Weremowicz S, Cantor RM, Barbieri RL, Morton CC. Cytogenetic abnormalities in uterine myomas are associated with myoma size. Mol Hum Reprod. 1998;4:1:83—86. https://doi. org/10.1093/molehr/4.1.83

17.        Hennig Y, Deichert U, Bonk U, Thode B, Bartnitzke S, Bullerdiek J. Chromosomal translocations affecting 12q14-15 but not deletions of the long arm of chromosome 7 associated with a growth advantage of uterine smooth muscle cells. Mol Hum Reprod. 1999;5:12:1150—1154. https://doi. org/10.1093/molehr/5.12.1150

18.        Mдkinen NN,  Miika Mehine M, Tolvanen J, Kaasinen E, Yilong Li Heli J. Lehtonen, Gentile M, Jian Yan, Enge M, Taipale M, Aavikko M, Katainen R, Virolainen E, Bцhling T, Taru A. Koski, Launonen V, Sjцberg J, Taipale J, Vahteristo P, Aaltonen LA. MED12, the mediator complex subunit 12 gene, is mutated at high frequency in uterine leiomyomas. Science. 2011;334:6053:252—255. https://doi. org/10.1126/science.1208930

19.        Mittal P, Yong-hyun Shin, Yatsenko S, Castro C, Surti U, Rajkovic A. Med12 gain-of-function mutation causes leiomyomas and genomic instability. J Clin Invest. 2015;125:8:3280—3284.  https://doi. org/10.1172/JCI81534

20.        Tommaso S, Massari S, Malvasi A, Vergara D, Maffia M, Greco M, Tinelli A. Selective genetic analysis of myoma pseudocapsule and potential biological impact on uterine fibroid medical therapy. Expert Opin Ther Targets. 2015;19:1:7—12. https://doi. org/10.1517/14728222.2014.975793

21.        Markowski ND, Tadayyon M, Bartnitzke S, Belge G, Maria Helmke B, Bullerdiek J. Cell cultures in uterine leiomyomas: Rapid disappearance of cells carrying MED12 mutations. Genes Chromosom Cancer. 2014;53:4:317—323.  https://doi. org/10.1186/s13039-014-0088-1

22.        Mehine M, Kaasinen E, Mдkinen N, Katainen R, Kдmpjдrvi K, Pitkдnen E, Heinonen H, Bьtzow R, Kilpivaara O, Kuosmanen A, Ristolainen H, Gentile M, Sjцberg J, Vahteristo P, Aaltonen L. Characterization of uterine leiomyomas by whole-genome sequencing. N Engl J Med. 2013;369:1:43—53. https://doi. org/10.1056/NEJMoa1302736

23.        Tomlinson IPM, Alam A, Rowan A, Bevan S, Kiuru M, Lehtonen R. Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer. Nat Genet. 2002;30(april):406—410. https://doi. org/10.1038/ng849

24.        Heidet L, Cohen-Solal L, Boye E, Thorner P, Kemper MJ, David A, Piet LL, Zhou J, Flinter F, Zhang X, Gubler MC, Antignac C. Novel COL4A5/COL4A6 deletions and further characterization of the diffuse leiomyomatosis-Alport syndrome (DL-AS) locus define the DL critical region. Cytogenet. Cell Genet. 1997;78:3–4:240—246. ISSN: 0301-0171.

25.        Li S, Zhang Y, Niu L, Wang Q, Lu X, Zhao X, Liang J, Liu H. AK000953 silencing can enhance the killing effect of danazol on uterine fibroids. Arch Gynecol Obs. 2015;295:5:1075—1081. PMID:25894338

26.        Al-Hendy A, Salama SA. Catechol-O-methyltransferase polymorphism is associated with increased uterine leiomyoma risk in different ethnic groups. Journal of the Society for Gynecologic Investigation. 2006;13:136—144. https://doi. org/10.21638/11701/spbu11.2016.310

27.        Hassan M, Zhang D, Salama S, Hamada F, Arafa H, Fouad H, Walker C, Al-Hendy A. Towards fibroid gene therapy: Adenovirus-mediated delivery of herpes simplex virus 1 thymidine kinase gene/ganciclovir shrinks uterine leiomyoma in the Eker rat model. Gynecol Obstet Invest. 2009;68:1:19—32. http://doi. org/10.1159/000209675

28.        Nair S, Curiel DT, Rajaratnam V, Thota C, Al-Hendy A. Targeting adenoviral vectors for enhanced gene therapy of uterine leiomyomas. Hum Reprod. 2013;28:9:2398—406. http://doi. org/10.1093/humrep/det275

29.        Abdelaziz M, Sherif L, ElKhiary M, Nair S, Shalaby S, Mohamed S, Eziba N, El-Lakany M, Curiel D, Ismail N, Diamond MP, Al-Hendy A. Targeted adenoviral vector demonstrates enhanced efficacy for In vivo gene therapy of uterine leiomyoma. Reprod Sci. 2016;23:4:464—474. http://doi. org/10.1177/1933719116630413

30.        Shalaby SM, Khater MK, Perucho AM, Mohamed SA, Helwa I, Laknaur A, Lebedyeva I, Liu Y, Diamond MP, Al-Hendy AA. Magnetic nanoparticles as a new approach to improve the efficacy of gene therapy against differentiated human uterine fibroid cells and tumor-initiating stem cells. Fertil Steril. 2016;105:6:1638—1648.e8. http://doi. org/10.1016/j. fertnstert.2016.03.001

31.        , Миома матки. Современное представление о патогенезе и факторах риска. Сибирское медицинское обозрение. 2015;91:1:22—27. [Shtokh E. A., Tskhai V. B. Myoma of the uterus. Modern understanding about pathogenesis and risk factors. Sibirskoe meditsinskoe obozrenie. 2015;91:1:22—27. (In Russ.)].

32.        Islam MS, Segars JH, Castellucci M, Ciarmela P. Dietary phytochemicals for possible preventive and therapeutic option of uterine fibroids: Signaling pathways as target. Pharmacol Reports. 2017;69:1:57—70. http://doi. org/10.1016/j. pharep.2016.10.013

33.        Shi Y, Hata Y, Lo RS, Massague J, Pavletich NP. A structural basis for mutational inactivation of the tumour suppressor Smad4. Nature. 1997;388:6637:87—93. http://doi. org/10.1038/40431

34.        Heldin CH, Miyazono K, Dijke P ten. TGF-beta signalling from cell membrane to nucleus through SMAD proteins. Nature. 1997;390:6659:465—471. http://doi. org/10.1038/37284

35.        Chegini N , Luo X, Ding L, Ripley D. The expression of Smads and transforming growth factor beta receptors in leiomyoma and myometrium and the effect of gonadotropin releasing hormone analogue therapy. Molecular and Cellular Endocrinology. 2003:9—16. http://doi. org/10.1016/j. mce.2003.08.007

36.        Engelman J, Luo J, Cantley LC. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet. 2006;7:8:606—619. http://doi. org/10.1038/nrg1879

37.        Ren Y, Yin H, Tian, Ruijuan C, Lihua Z, Yingjun L, Wanjun T, Xiang DG, Yu Z, Xi-Long. Different effects of epidermal growth factor on smooth muscle cells derived from human myometrium and from leiomyoma. Fertil Steril. 2011;96:4:1015—1020. https://doi. org/10.1016/j. fertnstert.2011.07.004

38.        Crabtree JS, Jelinsky SA, Harris HA, Choe SE, Cotreau MM, Kimberland ML, Wilson E, Saraf KA, Wei Liu, McCampbell AS, Dave B, Broaddus RR, Brown EL, Kao W, Skotnicki JS, Gharbia MA, Winneker RC, Walker parison of human and rat uterine leiomyomata: Identification of a dysregulated mammalian target of rapamycin pathway. Cancer Res. 2009:69:15:6171—6178. http://doi. org/10.1158/0008-5472.CAN-08-4471

39.        Sefton EC, Qiang W, Serna V, Kurita T, Wei J-J, Chakravarti D, Kim JJ. MK-2206, an AKT inhibitor, promotes caspase-independent cell death and inhibits leiomyoma growth. Endocrinology. 2013;154:11:4046—4057. http://doi. org/10.1210/en.2013-1389

40.        Varghese B, Koohestani F, McWilliams M, Colvin A, Gunewardena S, Kinsey WH, Nowak RA, Nothnick W. B., Chennathukuzhi VM. Loss of the repressor REST in uterine fibroids promotes aberrant G protein-coupled receptor 10 expression and activates mammalian target of rapamycin pathway. Proc Natl Acad Sci. U. S. A. 2013;110:6:2187—2192. http://doi. org/10.1073/pnas.1215759110

41.        Hoekstra AV, Sefton EC, Berry E, Lu Z, Hardt J, Marsh E, Yin P, Clardy J, Chakravarti D, Bulun S, Kim JJ. Progestins activate the AKT pathway in leiomyoma cells and promote survival. J Clin Endocrinol Metab. 2009;94:5:1768—1774. http://doi. org/10.1210/jc.2008-2093

42.        Friedman N, Shushan A, Rojansky N, Shveiky D, Levitzki R, Chaouat M, Ben-Bassat H. Targeting leiomyomas with all-trans-retinoic acid at phosphoinositide 3-kinase pathway suppression: Effective roles of ?-catenin and of signaling interactions. J Obstet Gynaecol Res. 2016;42:10:1343—1353. http://doi. org/10.1111/jog.13068